Ceftaroline fosamil for treatment of communityacquired pneumonia: Findings from FOCUS 1 and 2 and potential role in therapy

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 8, 2011, Pages 567-572

  Dimondi, V Paul ^a   Drew, Richard H ^a,b   Chen, Luke F ^b  

^a CAMPBELL UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

ceftaroline; ceftriaxone; cephalosporin; community acquired pneumonia; FOCUS; pneumonia

Indexed keywords

AZTREONAM; CEFTAROLINE FOSAMIL; CEFTRIAXONE; VANCOMYCIN;

ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; INSOMNIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA AND VOMITING; NONHUMAN; QT PROLONGATION; SIDE EFFECT; SKIN INFECTION; SUDDEN DEATH; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 80051720108     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.82     Document Type: Article

References (27)

1. Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: Results of a population-based study. Clin. Infect. Dis. 39(11), 1642-1650 (2004). (Pubitemid 39578539)
2. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: Implications for therapy of community-acquired bacterial pneumonia. Int. J. Antimicrob. Agents 36(3), 197-204 (2010). Provides more background on the changing resistance patterns of Streptococcus pneumoniae and discusses the clinical implications for the management of community-acquired pneumonia.
3. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007). (Pubitemid 46290553)
4. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin. Infect. Dis. 48(3), e23-e33 (2009).
5. Gertz RE, Li Z, Pimenta FC et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis. 201(5), 770-775 (2010).
6. Patel SN, Pillai DR, Pong-Porter S, McGeer A, Green K, Low DE. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J. Antimicrob. Chemother. 64(3), 659-660 (2009).
7. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 54(5), 1670-1677 (2010).
8. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP 2a by two anti-MRSA b-lactam antibiotics. J. Am. Chem. Soc. 130(29), 9212-9213 (2008). (Pubitemid 352031115)
9. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob. Agents Chemother. 53(3), 1271-1274 (2009). Evaluates ceftaroline's in vitro spectrum of activity and provides more information on the differences between the in vitro suceptibility profiles of ceftaroline versus ceftriaxone.
10. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob. Agents Chemother. 54(4), 1627-1632 (2010).
11. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51(10), 3612-3616 (2007). (Pubitemid 47519351)
12. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51(6), 641-650 (2010). The results of the CANVAS 1 and 2 trials were pivotal in the approval of ceftaroline for acute bacterial skin and skin structure infections.
13. File TM Jr, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: Randomized, doubled blinded, multicenter Phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin. Infect. Dis. 51(12), 1395-1405 (2010). The results of the Ceftaroline vs Ceftriaxone in Adults With Community-Acquired Pneumonia (FOCUS) 1 and 2 integrated analysis provided the safety, tolerability and efficacy data necessary for ceftaroline to receive US FDA approval for community-acquired pneumonia.
14. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob. Agents Chemother. 43(8), 1901-1908 (1999). (Pubitemid 29395183)
15. Kays M, Brown S. Prevalence of antibacterial resistance among Streptococcus pneumoniae isolates in the USA: PROTEKT US Years 1-3. Programs and Abstracts of the Infectious Diseases Society of America Annual Meeting. Boston, MA, USA, 30 September-3 October 2004 (Abstract 354).
16. Jacobs MR, Good CE, Windau AR et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 54(6), 2716-2719 (2010).
17. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare Fee-for-Service Program. N. Engl. J. Med. 360(14), 1418-1428 (2009).
18. Johnson D, Carriere KC, Jin Y, Marrie T. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality. J. Clin. Pharm. Ther. 29(3), 231-239 (2004). (Pubitemid 38901534)
19. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: Playing by the rules. Arch. Intern. Med. 169(16), 1525-1531 (2009).
20. Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD. Resource use and cost of care for patients hospitalised with community acquired pneumonia: Impact of adherence to Infectious Diseases Society of America Guidelines. PharmacoEconomics 22(11), 751-757 (2004). (Pubitemid 38998499)
21. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60(2), 300-311 (2007). (Pubitemid 47243878)
22. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. Activity of chequerboard combinations of ceftaroline and NXL104 versus b-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65(7), 1428-1432 (2010).
23. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(6), 2360-2366 (2009).
24. Jacqueline C, Amador G, Caillon J et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J. Antimicrob. Chemother. 65(8), 1749-1752 (2010).
25. Jacqueline C, Caillon J, Batard E et al. Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model. J. Antimicrob. Chemother. 65(10), 2264-2265 (2010).
26. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: A comparative study with linezolid and vancomycin. Antimicrob. Agents Chemother. 53(12), 5300-5302 (2009).
27. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51(9), 3397-3400 (2007). (Pubitemid 350067563)